RecruitingPhase 1Phase 2NCT07089121

Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders

Descartes-08 for Children, Adolescents and Young Adults With Childhood-onset Systemic Lupus Erythematosus, ANCA-associated Vasculitis, Juvenile Myasthenia Gravis, and Juvenile Dermatomyositis

Sponsor

Cartesian Therapeutics

Enrollment

50 participants

Start Date

Jan 14, 2026

Study Type

INTERVENTIONAL

Conditions

Juvenile Myasthenia Gravis ANCA Associated Vasculitis (AAV)Juvenile Dermatomyositis Childhood-onset Systemic Lupus Erythematous

Summary

Safety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis

Eligibility

Min Age: 12 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Descartes-08 for people with anca associated vasculitis (aav), childhood-onset systemic lupus erythematous, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 12 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDescartes-08

In part 1, three different doses will be administered to 3 participants with either disease indication to establish maximum tolerated dose In part 2, the MTD established in Part-1 will be administered as six once-weekly infusions to up to 10 participants per each of four baskets (cSLE, AAV, JDM and JMG) in an outpatient setting.